NEW YORK, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of INC Research Holdings, Inc. (INC Research) (Nasdaq:INCR), a leading global Phase I to IV contract research organization, commenced on The Nasdaq Stock Market on November 7, 2014.

INC Research provides a full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market through its service offerings and therapeutic expertise in multiple patient populations. With approximately 5,500 employees worldwide, INC Research has the global workforce to support clinical development programs of any size around the world.

"INC Research is committed to delivering therapeutic and operational expertise to accelerate clinical development programs and bring new treatments to market," said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. "We are proud to welcome INC Research to The Nasdaq Stock Market family and we look forward to supporting its growth as a public company."

"We are very pleased with the positive reception and investor interest on our listing with Nasdaq," said Jamie Macdonald, CEO, INC Research. "We believe that outsourcing clinical development services to CROs optimizes returns on R&D investments for biopharmaceutical companies and will continue to increase. INC Research is now in a stronger position to fund future growth, innovation and expansion plans that will bolster our capabilities as a leading global CRO."

Mr. Macdonald will lead the Nasdaq Stock Market Opening Bell ceremony in Times Square, New York on Monday, November 10, 2014 in celebration of INC Research's IPO.

By listing with Nasdaq, INC Research joins many of the world's largest and most revolutionary companies. Nasdaq has been the exchange of choice to 93 percent of healthcare companies listed in the U.S. markets year-to-date.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About INC Research

INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. We were ranked "Top CRO to Work With" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research. 

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com.

NDAQG

CONTACT: Media Relations Contacts:
         
         Will Briganti
         (646) 441-5012
         william.briganti@nasdaq.com
         
         Christine Barna
         (646) 441-5310
         Christine.Barna@nasdaq.com

Nasdaq logo